{"id":1487,"date":"2021-06-04T09:29:32","date_gmt":"2021-06-04T08:29:32","guid":{"rendered":"https:\/\/blogs.bmj.com\/sti\/?p=1487"},"modified":"2021-06-04T16:28:53","modified_gmt":"2021-06-04T15:28:53","slug":"hpv-vaccine-uptake-achievements-and-challenges","status":"publish","type":"post","link":"https:\/\/blogs.bmj.com\/sti\/2021\/06\/04\/hpv-vaccine-uptake-achievements-and-challenges\/","title":{"rendered":"HPV Vaccine Uptake: Challenges and Opportunities"},"content":{"rendered":"

 <\/p>\n

\"\"<\/a><\/p>\n

Welcome to the fourth episode of the STI BMJ 2021 Podcast series. Please join Dr. Fabiola Martin in interviewing Professors Anna Maria Geretti, Carlo Giaquinto, and Ian Frazer about human papillomavirus vaccines and vaccination programmes.<\/p>\n

The first HPV vaccine was approved in 2006. Fifteen years later, more than 100 countries have added the vaccine to routine childhood vaccination schedules. Reflecting the high vaccine efficacy in preventing infection with cancer-inducing HPV types, the World Health Organization is aiming for the elimination of cervical cancer by 2030<\/a>.<\/p>\n

Is this target too ambitious?<\/p>\n

Despite the established benefits and good tolerability of HPV vaccines, some countries are seeing sluggish uptake of the first dose, with coverage falling further for subsequent doses. In this podcast, we hear about the falling vaccine uptake in Italy and the successful vaccine roll-out in Australia. What can we learn from these experiences?<\/p>\n

Join us in this episode of STI Podcast here<\/a>!<\/p>\n